Lowest Price Guaranteed
Slides
222
Last Updated
August 2026
View Count
25509
1. PREFACE
1.1. Allogeneic Cell Therapy Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Allogeneic Cell Therapy
3.2. Manufacturing Process of Allogeneic Cell Therapy
3.3. Advantages Offered by Allogeneic Cell Therapy
3.4. Challenges Associated with Allogeneic Cell Therapy
3.5. Recent Developments in Allogeneic Cell Therapy Industry
3.6. Future Perspectives
4. MARKET LANDSCAPE
4.1. Allogeneic Cell Therapies: Market Landscape
4.1.1. Analysis by Phase of Development
4.1.2. Analysis by Route of Administration
4.1.3. Analysis by Type of Cell Therapy
4.1.4. Analysis by Source of Cell
4.1.5. Analysis by Dosing Frequency
4.1.6. Analysis by Type of Therapy
4.1.7. Analysis by Target Patient Segment
4.1.8. Analysis by Target Indication
4.1.9. Analysis by Therapeutic Area
4.2. Allogeneic Cell Therapies: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Most Active Players: Analysis by Number of Therapies
5. PARTNERSHIPS AND COLLABORATIONS
5.1. Chapter Overview
5.2. Partnership Models
5.3. Allogeneic Cell Therapies: Partnerships and Collaborations
5.3.1. Analysis by Year of Partnership
5.3.2. Analysis by Type of Partnership
5.3.3. Analysis by Year and Type of Partnership
5.3.4. Analysis by Type of Cell Therapy
5.3.5. Analysis by Therapeutic Area
5.3.6. Analysis by Type of Partner
5.3.7. Most Active Players: Analysis by Number of Partnerships
5.3.8. Analysis by Geography
5.3.8.1. Intercontinental and Intracontinental Deals
5.3.8.2. Local and International Deals
6. FUNDING AND INVESTMENTS
6.1. Chapter Overview
6.2. Types of Funding
6.3. Allogeneic Cell Therapies: Funding and Investments
6.3.1. Analysis by Year of Investment
6.3.2. Analysis by Amount Invested
6.3.3. Analysis by Type of Funding
6.3.4. Analysis of Amount Invested by Type of Funding
6.3.5. Analysis of Amount Invested by Year and Type of Funding
6.3.6. Analysis by Type of Investor
6.3.7. Analysis by Type of Therapy
6.3.8. Analysis by Geography
6.3.9. Leading Investors: Analysis by Number of Instances
6.3.10. Most Active Players: Analysis by Number of Instances
6.3.11. Most Active Players: Analysis by Amount Invested
7. CLINICAL TRIAL ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Allogeneic Cell Therapies: Clinical Trial Analysis
7.2.1. Analysis by Trial Registration Year
7.2.2. Analysis by Trial Status
7.2.3. Analysis by Trial Registration Year and Trial Status
7.2.4. Analysis by Trial Registration Year and Patients Enrolled
7.2.5. Analysis by Trial Status and Patients Enrolled
7.2.6. Analysis by Trial Phase
7.2.7. Analysis by Study Design
7.2.8. Analysis by Trial Status, Trial Phase and Geography
7.2.9. Analysis by Type of Sponsor
7.2.10. Most Active Industry Players: Analysis by Number of Trials
7.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
7.2.12. Analysis by Geography
8. KEY OPINION LEADERS
8.1. Methodology and Key Parameters
8.2. Allogeneic Cell Therapies: Key Opinion Leaders (KOLs)
8.2.1. Analysis by Type of KOL
8.2.2. Analysis by Qualification
8.2.3. Analysis by Type of Organization
8.2.4. Analysis by Affiliated Organization
8.2.5. Analysis by Target Disease Indication
8.2.6. Analysis by Geographical Location of KOLs
8.2.7. Most Prominent KOLs: Peer Group 1 (Principal Investigators)
8.2.8. Most Prominent KOLs: Peer Group 2 (Study Directors)
8.2.9. Most Prominent KOLs: Peer Group 3 (Study Chair)
8.2.10. Most Prominent KOLs: Analysis by RA Score
9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Global Allogeneic Cell Therapy Market, 2023-2035
9.3.1. Allogeneic Cell Therapy Market: Distribution by Type of Cell Therapy, 2023 and 2035
9.3.1.1. Allogeneic Cell Therapy Market for Stem Cell Therapies, 2023-2035
9.3.1.2. Allogeneic Cell Therapy Market for Virus-specific T-cell Therapies, 2023-2035
9.3.1.3. Allogeneic Cell Therapy Market for Regulatory T-cell Therapies, 2029-2035
9.3.2. Allogeneic Cell Therapy Market: Distribution by Source of Cell, 2023 and 2035
9.3.2.1. Allogeneic Cell Therapy Market for Bone Marrow / Matrix-derived Therapies, 2023-2035
9.3.2.2. Allogeneic Cell Therapy Market for Adipose Tissue-derived Therapies, 2023-2035
9.3.2.3. Allogeneic Cell Therapy Market for Peripheral Blood-derived Therapies, 2025-2035
9.3.2.4. Allogeneic Cell Therapy Market for Umbilical Cord-derived Therapies, 2023-2035
9.3.2.5. Allogeneic Cell Therapy Market for Placenta-derived Therapies, 2023-2035
9.3.2.6. Allogeneic Cell Therapy Market for Others, 2023-2035
9.3.3. Allogeneic Cell Therapy Market: Distribution by Target Indication, 2023 and 2035
9.3.3.1. Allogeneic Cell Therapy Market for Infectious Disease, 2023-2035
9.3.3.2. Allogeneic Cell Therapy Market for Chronic Heart Failure, 2023-2035
9.3.3.3. Allogeneic Cell Therapy Market for Crohn’s Disease 2023-2035
9.3.3.4. Allogeneic Cell Therapy Market for Ischemic Stroke, 2024-2035
9.3.3.5. Allogeneic Cell Therapy Market for Hematological Cancer, 2023-2035
9.3.3.6. Allogeneic Cell Therapy Market for Bone Diseases 2023-2035
9.3.3.7. Allogeneic Cell Therapy Market for Critical Limb Ischemia, 2023-2035
9.3.3.8. Allogeneic Cell Therapy Market for Graft versus Host Disease, 2023-2035
9.3.3.9. Allogeneic Cell Therapy Market for Duchenne Muscular Dystrophy, 2026-2035
9.3.3.10. Allogeneic Cell Therapy Market for Epidermolysis Bullosa, 2027-2035
9.3.3.11. Allogeneic Cell Therapy Market for Diabetic Foot Ulcer, 2023-2035
9.3.3.12. Allogeneic Cell Therapy Market for Others, 2023-2035
9.3.4. Allogeneic Cell Therapy Market: Distribution by Therapeutic Area, 2023 and 2035
9.3.4.1. Allogeneic Cell Therapy Market for Post-Transplant Infections, 2023-2035
9.3.4.2. Allogeneic Cell Therapy Market for Cardiovascular Disorders, 2023-2035
9.3.4.3. Allogeneic Cell Therapy Market for Autoimmune / Inflammatory Disorders, 2023-2035
9.3.4.4. Allogeneic Cell Therapy Market for Cerebrovascular Disorders, 2024-2035
9.3.4.5. Allogeneic Cell Therapy Market for Oncological Disorders, 2023-2035
9.3.4.6. Allogeneic Cell Therapy Market for Musculoskeletal Disorders, 2023-2035
9.3.4.7. Allogeneic Cell Therapy Market for Neurological Disorders, 2023-2035
9.3.4.8. Allogeneic Cell Therapy Market for Genetic Disorders, 2026-2035
9.3.4.9. Allogeneic Cell Therapy Market for Others, 2023-2035
9.3.5. Allogeneic Cell Therapy Market: Distribution by Key Geographical Regions, 2023 and 2035
9.3.5.1. Allogeneic Cell Therapy Market in North America, 2023-2035
9.3.5.1.1. Allogeneic Cell Therapy Market in the US, 2023-2035
9.3.5.1.2. Allogeneic Cell Therapy Market in Canada, 2024-2035
9.3.5.2. Allogeneic Cell Therapy Market in Europe, 2023-2035
9.3.5.2.1. Allogeneic Cell Therapy Market in the UK, 2023-2035
9.3.5.2.2. Allogeneic Cell Therapy Market in Germany, 2023-2035
9.3.5.2.3. Allogeneic Cell Therapy Market in France, 2023-2035
9.3.5.2.4. Allogeneic Cell Therapy Market in Italy, 2023-2035
9.3.5.2.5. Allogeneic Cell Therapy Market in Spain, 2023-2035
9.3.5.2.6. Allogeneic Cell Therapy Market in Rest of Europe, 2023-2035
9.3.5.3. Allogeneic Cell Therapy Market in Asia-Pacific and Rest of the World, 2023-2035
9.3.5.3.1. Allogeneic Cell Therapy Market in India, 2023-2035
9.3.5.3.2. Allogeneic Cell Therapy Market in Australia, 2026-2035
9.3.5.3.3. Allogeneic Cell Therapy Market in Taiwan, 2027-2035
9.3.5.3.4. Allogeneic Cell Therapy Market in Japan, 2023-2035
9.3.5.3.5. Allogeneic Cell Therapy Market in Korea, 2023-2035
9.3.5.3.6. Allogeneic Cell Therapy Market in Malaysia, 2023-2035
9.3.5.3.7. Allogeneic Cell Therapy Market in Israel, 2023-2035
9.4. Allogeneic Cell Therapy Market: Product-wise Sales Forecast, 2023-2035
9.4.1. Revascor / MPC-150-IM / Rexlemestrocel-L
9.4.1.1. Sales Forecast (USD Million)
9.4.1.2. Net Present Value
9.4.1.3. Value Creation Analysis
9.4.2. Alofisel / Darvadstrocel / Cx601
9.4.2.1. Sales Forecast (USD Million)
9.4.2.2. Net Present Value
9.4.2.3. Value Creation Analysis
9.4.3. MultiStem® (Athersys)
9.4.3.1. Sales Forecast (USD Million)
9.4.3.2. Net Present Value
9.4.3.3. Value Creation Analysis
9.4.4. Tab-cel® / tabelecleucel / ATA129
9.4.4.1. Sales Forecast (USD Million)
9.4.4.2. Net Present Value
9.4.4.3. Value Creation Analysis
9.4.5. MDR-101
9.4.5.1. Sales Forecast (USD Million)
9.4.5.2. Net Present Value
9.4.5.3. Value Creation Analysis
9.4.6. PLX-PAD
9.4.6.1. Sales Forecast (USD Million)
9.4.6.2. Net Present Value
9.4.6.3. Value Creation Analysis
9.4.7. OMISIRGE / Omidubicel-onlv
9.4.7.1. Sales Forecast (USD Million)
9.4.7.2. Net Present Value
9.4.7.3. Value Creation Analysis
9.4.8. Orca-T
9.4.8.1. Sales Forecast (USD Million)
9.4.8.2. Net Present Value
9.4.8.3. Value Creation Analysis
9.4.9. Ryoncil
9.4.9.1. Sales Forecast (USD Million)
9.4.9.2. Net Present Value
9.4.9.3. Value Creation Analysis
9.4.10. Stempeucel®
9.4.10.1. Sales Forecast (USD Million)
9.4.10.2. Net Present Value
9.4.10.3. Value Creation Analysis
9.4.11. Viralym-M / ALVR105 / Posoleucel
9.4.11.1. Sales Forecast (USD Million)
9.4.11.2. Net Present Value
9.4.11.3. Value Creation Analysis
9.4.12. Trinity Evolution®
9.4.12.1. Sales Forecast (USD Million)
9.4.12.2. Net Present Value
9.4.12.3. Value Creation Analysis
9.4.13. CAP-1002
9.4.13.1. Sales Forecast (USD Million)
9.4.13.2. Net Present Value
9.4.13.3. Value Creation Analysis
9.4.14. Osteocel® Plus
9.4.14.1. Sales Forecast (USD Million)
9.4.14.2. Net Present Value
9.4.14.3. Value Creation Analysis
9.4.15. MPC-06-ID / Rexlemestrocel-L
9.4.15.1. Sales Forecast (USD Million)
9.4.15.2. Net Present Value
9.4.15.3. Value Creation Analysis
9.4.16. AB-205 / E-CEL cells
9.4.16.1. Sales Forecast (USD Million)
9.4.16.2. Net Present Value
9.4.16.3. Value Creation Analysis
9.4.17. allo-APZ2-OTS
9.4.17.1. Sales Forecast (USD Million)
9.4.17.2. Net Present Value
9.4.17.3. Value Creation Analysis
9.4.18. Trinity ELITE
9.4.18.1. Sales Forecast (USD million)
9.4.18.2. Net Present Value
9.4.18.3. Value Creation Analysis
9.4.19. CYP-004
9.4.19.1. Sales Forecast (USD Million)
9.4.19.2. Net Present Value
9.4.19.3. Value Creation Analysis
9.4.20. Cytovir CMV T-cells
9.4.20.1. Sales Forecast (USD Million)
9.4.20.2. Net Present Value
9.4.20.3. Value Creation Analysis
9.4.21. CARTISTEM®
9.4.21.1. Sales Forecast (USD Million)
9.4.21.2. Net Present Value
9.4.21.3. Value Creation Analysis
9.4.22. Grafix®
9.4.22.1. Sales Forecast (USD Million)
9.4.22.2. Net Present Value
9.4.22.3. Value Creation Analysis
9.4.23. ELIXCYTE
9.4.23.1. Sales Forecast (USD Million)
9.4.23.2. Net Present Value
9.4.23.3. Value Creation Analysis
9.4.24. TEMCELL® HS
9.4.24.1. Sales Forecast (USD Million)
9.4.24.2. Net Present Value
9.4.24.3. Value Creation Analysis
9.4.25. ALLO-ASC-DFU
9.4.25.1. Sales Forecast (USD Million)
9.4.25.2. Net Present Value
9.4.25.3. Value Creation Analysis
10. EXECUTIVE INSIGHTS
10.1. Chapter Overview
10.2. Glycostem Therapeutics
10.2.1. Company Snapshot
10.2.2. Interview Transcript: Troels Jordansen (Chief Executive Officer)
10.3. Mesoblast
10.3.1. Company Snapshot
10.3.2. Interview Transcript
10.4. Triumvira Immunologics
10.4.1. Company Snapshot
10.5. Celyad Oncology
10.5.1. Company Snapshot
10.5.2. Interview Transcript
11. APPENDIX I: TABULATED DATA
12. APPENDIX I1: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Funding and Investment Analysis
Figure 2.4 Executive Summary: Clinical Trial Analysis
Figure 2.5 Executive Summary: Key Opinion Leaders
Figure 2.6 Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1 Manufacturing Process of Allogeneic Cell Therapy
Figure 3.2 Advantages Offered by Allogeneic Cell Therapy
Figure 3.3 Challenges Associated with Allogeneic Cell Therapy
Figure 4.1 Allogeneic Cell Therapies: Distribution by Phase of Development
Figure 4.2 Allogeneic Cell Therapies: Distribution by Route of Administration
Figure 4.3 Allogeneic Cell Therapies: Distribution by Type of Cell Therapy
Figure 4.4 Allogeneic Cell Therapies: Distribution by Source of Cell
Figure 4.5 Allogeneic Cell Therapies: Distribution by Dosing Frequency
Figure 4.6 Allogeneic Cell Therapies: Distribution by Type of Therapy
Figure 4.7 Allogeneic Cell Therapies: Distribution by Target Patient Segment
Figure 4.8 Allogeneic Cell Therapies: Distribution by Target Indication
Figure 4.9 Allogeneic Cell Therapies: Distribution by Therapeutic Area
Figure 4.10 Allogeneic Cell Therapies Developers: Distribution by Year of Establishment
Figure 4.11 Allogeneic Cell Therapies Developers: Distribution by Company Size
Figure 4.12 Allogeneic Cell Therapies Developers: Distribution by Location of Headquarters
Figure 4.13 Most Active Players: Distribution by Number of Therapies
Figure 5.1 Partnerships and Collaborations: Distribution by Year of Partnership, 2019-2023
Figure 5.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 5.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 5.4 Partnerships and Collaborations: Distribution by Type of Cell Therapy
Figure 5.5 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 5.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 5.7 Most Active Players: Distribution by Number of Partnerships
Figure 5.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 5.9 Partnerships and Collaborations: Local and International Deals
Figure 6.1 Funding and Investments: Distribution by Year of Investment, 2019-2023
Figure 6.2 Funding and Investments: Distribution by Amount Invested (USD Million)
Figure 6.3 Funding and Investments: Distribution by Type of Funding
Figure 6.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 6.5 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Figure 6.6 Funding and Investments: Distribution by Type of Investor
Figure 6.7 Funding and Investments: Distribution by Type of Therapy
Figure 6.8 Funding and Investments: Distribution by Geography (Region-wise)
Figure 6.9 Funding and Investments: Distribution by Geography (Country-wise)
Figure 6.10 Leading Investors: Distribution by Number of Instances
Figure 6.11 Most Active Players: Distribution by Number of Instances
Figure 6.12 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Distribution by Trial Registration Year, 2019-2023
Figure 7.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Figure 7.6 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
Figure 7.7 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.8 Clinical Trial Analysis: Distribution by Study Design
Figure 7.9 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Figure 7.10 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 7.11 Most Active Industry Players: Analysis by Number of Trials
Figure 7.12 Most Active Non-Industry Players: Analysis by Number of Trials
Figure 7.13 Clinical Trial Analysis: Distribution by Geography and Trial Status (Number of Trials)
Figure 7.14 Clinical Trial Analysis: Distribution by Geography and Trial Status (Patients Enrolled)
Figure 8.1 Allogeneic Cell Therapies KOL Analysis: Distribution by Type of KOL
Figure 8.2 Allogeneic Cell Therapies KOL Analysis: Distribution by Qualification
Figure 8.3 Allogeneic Cell Therapies KOL Analysis: Distribution by Type of Organization
Figure 8.4 Allogeneic Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 8.5 Allogeneic Cell Therapies KOL Analysis: Distribution by Target Disease Indication
Figure 8.6 Allogeneic Cell Therapies KOL Analysis: Geographical Distribution of KOLs (Region-wise)
Figure 8.7 Allogeneic Cell Therapies KOL Analysis: Geographical Distribution of KOLs (Country-wise)
Figure 8.8 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
Figure 8.9 Most Prominent KOLs: Peer Group 2 (Study Directors)
Figure 8.10 Most Prominent KOLs: Peer Group 3 (Study Chair)
Figure 8.11 Most Prominent KOLs: Distribution by RA score
Figure 9.1 Global Allogeneic Cell Therapy Market, 2023-2035 (USD Million)
Figure 9.2 Allogeneic Cell Therapy Market: Distribution by Type of Cell Therapy, 2023 and 2035 (USD Million)
Figure 9.3 Allogeneic Cell Therapy Market for Stem Cell Therapies, 2023-2035 (USD Million)
Figure 9.4 Allogeneic Cell Therapy Market for Virus-Specific T-cell Therapies, 2023-2035 (USD Million)
Figure 9.5 Allogeneic Cell Therapy Market for Regulatory T-cell Therapies, 2029-2035 (USD Million)
Figure 9.6 Allogeneic Cell Therapy Market: Distribution by Source of Cell, 2023 and 2035 (USD Million)
Figure 9.7 Allogeneic Cell Therapy Market for Bone Marrow / Matrix-derived Therapies, 2023-2035 (USD Million)
Figure 9.8 Allogeneic Cell Therapy Market for Adipose Tissue-derived Therapies, 2023-2035 (USD Million)
Figure 9.9 Allogeneic Cell Therapy Market for Peripheral Blood-derived Therapies, 2025-2035 (USD Million)
Figure 9.10 Allogeneic Cell Therapy Market for Umbilical Cord-derived Therapies, 2023-2035 (USD Million)
Figure 9.11 Allogeneic Cell Therapy Market for Placenta-derived Therapies, 2023-2035 (USD Million)
Figure 9.12 Allogeneic Cell Therapy Market for Others, 2023-2035 (USD Million)
Figure 9.13 Allogeneic Cell Therapy Market: Distribution by Target Indication, 2023 and 2035 (USD Million)
Figure 9.14 Allogeneic Cell Therapy Market for Infectious Disease, 2023-2035 (USD Million)
Figure 9.15 Allogeneic Cell Therapy Market for Chronic Heart Failure, 2023-2035 (USD Million)
Figure 9.16 Allogeneic Cell Therapy Market for Crohn’s Disease 2023-2035 (USD Million)
Figure 9.17 Allogeneic Cell Therapy Market for Ischemic Stroke, 2024-2035 (USD Million)
Figure 9.18 Allogeneic Cell Therapy Market for Hematological Cancer, 2023-2035 (USD Million)
Figure 9.19 Allogeneic Cell Therapy Market for Bone Disease, 2023-2035 (USD Million)
Figure 9.20 Allogeneic Cell Therapy Market for Critical Limb Ischemia, 2023-2035 (USD Million)
Figure 9.21 Allogeneic Cell Therapy Market for Graft versus Host Disease, 2023-2035 (USD Million)
Figure 9.22 Allogeneic Cell Therapy Market for Duchenne Muscular Dystrophy, 2026-2035 (USD Million)
Figure 9.23 Allogeneic Cell Therapy Market for Epidermolysis Bullosa, 2027-2035 (USD Million)
Figure 9.24 Allogeneic Cell Therapy Market for Diabetic Foot Ulcer, 2023-2035 (USD Million)
Figure 9.25 Allogeneic Cell Therapy Market for Others, 2023-2035 (USD Million)
Figure 9.26 Allogeneic Cell Therapy Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Million)
Figure 9.27 Allogeneic Cell Therapy Market for Post-Transplant Infections, 2023-2035 (USD Million)
Figure 9.28 Allogeneic Cell Therapy Market for Cardiovascular Disorders, 2023-2035 (USD Million)
Figure 9.29 Allogeneic Cell Therapy Market for Autoimmune / Inflammatory Disorders 2023-2035 (USD Million)
Figure 9.30 Allogeneic Cell Therapy Market for Cerebrovascular Disorders, 2024-2035 (USD Million)
Figure 9.31 Allogeneic Cell Therapy Market for Oncological Disorders, 2023-2035 (USD Million)
Figure 9.32 Allogeneic Cell Therapy Market for Musculoskeletal Disorders, 2023-2035 (USD Million)
Figure 9.33 Allogeneic Cell Therapy Market for Neurological Disorders, 2023-2035 (USD Million)
Figure 9.34 Allogeneic Cell Therapy Market for Genetic Disorders, 2026-2035 (USD Million)
Figure 9.35 Allogeneic Cell Therapy Market for Others, 2023-2035 (USD Million)
Figure 9.36 Allogeneic Cell Therapy Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Figure 9.37 Allogeneic Cell Therapy Market in North America, 2023-2035 (USD Million)
Figure 9.38 Allogeneic Cell Therapy Market in the US, 2023-2035 (USD Million)
Figure 9.39 Allogeneic Cell Therapy Market in Canada, 2024-2035 (USD Million)
Figure 9.40 Allogeneic Cell Therapy Market in Europe, 2023-2035 (USD Million)
Figure 9.41 Allogeneic Cell Therapy Market in the UK, 2023-2035 (USD Million)
Figure 9.42 Allogeneic Cell Therapy Market in Germany, 2023-2035 (USD Million)
Figure 9.43 Allogeneic Cell Therapy Market in France, 2023-2035 (USD Million)
Figure 9.44 Allogeneic Cell Therapy Market in Spain, 2023-2035 (USD Million)
Figure 9.45 Allogeneic Cell Therapy Market in Italy, 2023-2035 (USD Million)
Figure 9.46 Allogeneic Cell Therapy Market in Rest of Europe, 2023-2035 (USD Million)
Figure 9.47 Allogeneic Cell Therapy Market in Asia-Pacific and Rest of the World, 2023-2035 (USD Million)
Figure 9.48 Allogeneic Cell Therapy Market in India, 2023-2035 (USD Million)
Figure 9.49 Allogeneic Cell Therapy Market in Australia, 2026-2035 (USD Million)
Figure 9.50 Allogeneic Cell Therapy Market in Taiwan, 2027-2035 (USD Million)
Figure 9.51 Allogeneic Cell Therapy Market in Japan, 2023-2035 (USD Million)
Figure 9.52 Allogeneic Cell Therapy Market in Korea, 2023-2035 (USD Million)
Figure 9.53 Allogeneic Cell Therapy Market in Malaysia, 2023-2035 (USD Million)
Figure 9.54 Allogeneic Cell Therapy Market in Israel, 2023-2035 (USD Million)
Figure 9.55 Revascor / MPC-150-IM / Rexlemestrocel-L (Mesoblast): Sales Forecast, till 2035 (USD Million)
Figure 9.56 Alofisel / Darvadstrocel / Cx601 (Takeda): Sales Forecast, till 2035 (USD Million)
Figure 9.57 MultiStem® (Athersys): Sales Forecast, till 2035 (USD Million)
Figure 9.58 Tab-cel® / tabelecleucel / ATA129 (Atara Biotherapeutics): Sales Forecast, till 2035 (USD Million)
Figure 9.59 MDR-101 (Medeor Therapeutics): Sales Forecast, till 2035 (USD Million)
Figure 9.60 PLX-PAD (Pluristem Therapeutics): Sales Forecast, till 2035 (USD Million)
Figure 9.61 OMISIRGE / Omidubicel-onlv (Gamida Cell): Sales Forecast, till 2035 (USD Million)
Figure 9.62 Orca-T (Orca Bio): Sales Forecast, till 2035 (USD Million)
Figure 9.63 Ryoncil (Mesoblast): Sales Forecast, till 2035 (USD Million)
Figure 9.64 Stempeucel® (Stempeutics Research): Sales Forecast, till 2035 (USD Million)
Figure 9.65 Viralym-M / ALVR105 / Posoleucel (Allovir): Sales Forecast, till 2035 (USD Million)
Figure 9.66 Trinity Evolution® (Orthofix): Sales Forecast, till 2035 (USD Million)
Figure 9.67 CAP-1002 (Capricor Therapeutics): Sales Forecast, till 2035 (USD Million)
Figure 9.68 Osteocel® Plus (NuVasive): Sales Forecast, till 2035 (USD Million)
Figure 9.69 MPC-06-ID / Rexlemestrocel-L (Mesoblast): Sales Forecast, till 2035 (USD Million)
Figure 9.70 AB-205 / E-CEL cells (Angiocrine Bioscience): Sales Forecast, till 2035 (USD Million)
Figure 9.71 allo-APZ2-OTS (RHEACELL): Sales Forecast, till 2035 (USD Million)
Figure 9.72 Trinity ELITE (Orthofix): Sales Forecast, till 2035 (USD Million)
Figure 9.73 CYP-004 (Cynata Therapeutics): Sales Forecast, till 2035 (USD Million)
Figure 9.74 Cytovir CMV T-cells (Kuur Therapeutics): Sales Forecast, till 2035 (USD Million)
Figure 9.75 CARTISTEM® (Medipost): Sales Forecast, till 2035 (USD Million)
Figure 9.76 Grafix® (Osiris Therapeutics): Sales Forecast, till 2035 (USD Million)
Figure 9.77 ELIXCYTE (UnicoCell Biomed): Sales Forecast, till 2035 (USD Million)
Figure 9.78 TEMCELL® HS (JCR Pharmaceutical / Mesoblast): Sales Forecast, till 2035 (USD Million)
Figure 9.79 ALLO-ASC-DFU (Anterogen): Sales Forecast, till 2035 (USD Million)
Table 4.1 List of Allogeneic Cell Therapies
Table 4.2 List of Allogeneic Cell Therapies Developers
Table 5.1 Allogeneic Cell Therapies: List of Partnerships and Collaborations, 2019-2023
Table 6.1 Allogeneic Cell Therapies: List of Funding and Investments, 2019-2023
Table 7.1. Allogeneic Cell Therapies: List of Clinical Trials, 2019-2023
Table 8.1. Allogeneic Cell Therapies: List of Key Opinion Leaders (KOLs)
Table 9.1 Allogeneic Cell Therapies: List of Forecasted Therapies
Table 11.1 Market Landscape: Distribution by Phase of Development
Table 11.2 Market Landscape: Distribution by Route of Administration
Table 11.3 Market Landscape: Distribution by Type of Cell Therapy
Table 11.4 Market Landscape: Distribution by Source of Cell
Table 11.5 Market Landscape: Distribution by Dosing Frequency
Table 11.6 Market Landscape: Distribution by Type of Therapy
Table 11.7 Market Landscape: Distribution by Target Patient Segment
Table 11.8 Market Landscape: Distribution by Target Indication
Table 11.9 Market Landscape: Distribution by Therapeutic Area
Table 11.10 Market Landscape: Distribution by Year of Establishment
Table 11.11 Market Landscape: Distribution by Company Size
Table 11.12 Market Landscape: Distribution by Location of Headquarters
Table 11.13 Market Landscape: Distribution by Number of Therapies
Table 11.14 Partnerships and Collaborations: Distribution by Year of Partnership, 2019-2023
Table 11.15 Partnerships and Collaborations: Distribution by Type of Partnership
Table 11.16 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 11.17 Partnerships and Collaborations: Distribution by Type of Cell Therapy
Table 11.18 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 11.19 Partnerships and Collaborations: Distribution by Type of Partner
Table 11.20 Most Active Players: Distribution by Number of Partnerships
Table 11.21 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 11.22 Partnerships and Collaborations: Local and International Deals
Table 11.23 Funding and Investments: Distribution by Year of Investment, 2019-2023
Table 11.24 Funding and Investments: Distribution by Amount Invested (USD Million)
Table 11.25 Funding and Investments: Distribution by Type of Funding
Table 11.26 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Table 11.27 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Table 11.28 Funding and Investments: Distribution by Type of Investor
Table 11.29 Funding and Investments: Distribution by Type of Therapy
Table 11.30 Funding and Investments: Distribution by Geography (Region-wise)
Table 11.31 Funding and Investments: Distribution by Geography (Country-wise)
Table 11.32 Leading Investors: Distribution by Number of Instances
Table 11.33 Most Active Players: Distribution by Number of Instances
Table 11.34 Most Active Players: Distribution by Amount Invested (USD Million)
Table 11.35 Clinical Trial Analysis: Distribution by Trial Registration Year, 2019-2023
Table 11.36 Clinical Trial Analysis: Distribution by Trial Status
Table 11.37 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 11.38 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Table 11.39 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
Table 11.40 Clinical Trial Analysis: Distribution by Trial Phase
Table 11.41 Clinical Trial Analysis: Distribution by Study Design
Table 11.42 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Table 11.43 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 11.44 Most Active Industry Players: Analysis by Number of Trials
Table 11.45 Most Active Non-Industry Players: Analysis by Number of Trials
Table 11.46 Clinical Trial Analysis: Distribution by Geography and Trial Status (Number of Trials)
Table 11.47 Clinical Trial Analysis: Distribution by Geography and Trial Status (Patients Enrolled)
Table 11.48 Allogeneic Cell Therapies KOL Analysis: Distribution by Type of KOL
Table 11.49 Allogeneic Cell Therapies KOL Analysis: Distribution by Qualification
Table 11.50 Allogeneic Cell Therapies KOL Analysis: Distribution by Type of Organization
Table 11.51 Allogeneic Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Table 11.52 Allogeneic Cell Therapies KOL Analysis: Distribution by Target Disease Indication
Table 11.53 Allogeneic Cell Therapies KOL Analysis: Distribution by Geographical Location of KOLs
Table 11.54 Most Prominent KOLs: Distribution by RA score
Table 11.55 Global Allogeneic Cell Therapy Market: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.56 Allogeneic Cell Therapy Market: Distribution by Type of Cell Therapy, 2023 and 2035 (USD Million)
Table 11.57 Allogeneic Cell Therapy Market for Stem Cell Therapies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.58 Allogeneic Cell Therapies Market for Virus-specific T-cell Therapies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.59 Allogeneic Cell Therapy Market for Regulatory T-cell Therapies: Conservative, Base and Optimistic Scenarios, 2029-2035 (USD Million)
Table 11.60 Allogeneic Cell Therapy Market: Distribution by Source of Cell, 2023 and 2035 (USD Million)
Table 11.61 Allogeneic Cell Therapy Market for Bone Marrow / Matrix-derived Therapies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.62 Allogeneic Cell Therapy Market for Adipose Tissue-derived Therapies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.63 Allogeneic Cell Therapy Market for Umbilical Cord-derived Therapies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.64 Allogeneic Cell Therapy Market for Peripheral Blood-derived Therapies: Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Million)
Table 11.65 Allogeneic Cell Therapy Market for Placenta-derived Therapies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.66 Allogeneic Cell Therapy Market for Others: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.67 Allogeneic Cell Therapy Market: Distribution by Target Indication, 2023 and 2035 (USD Million)
Table 11.68 Allogeneic Cell Therapy Market for Infectious Disease: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.69 Allogeneic Cell Therapy Market for Chronic Heart Failure: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.70 Allogeneic Cell Therapy Market for Crohn’s Disease: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.71 Allogeneic Cell Therapy Market for Ischemic Stroke: Conservative, Base and Optimistic Scenarios, 2024-2035 (USD Million)
Table 11.72 Allogeneic Cell Therapy Market for Hematological Cancer: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.73 Allogeneic Cell Therapy Market for Bone Disease: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.74 Allogeneic Cell Therapy Market for Critical Limb Ischemia: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.75 Allogeneic Cell Therapy Market for Graft versus Host Disease: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.76 Allogeneic Cell Therapy Market for Duchenne Muscular Dystrophy: Conservative, Base and Optimistic Scenarios, 2026-2035 (USD Million)
Table 11.77 Allogeneic Cell Therapy Market for Epidermolysis Bullosa: Conservative, Base 8and Optimistic Scenarios, 2027-2035 (USD Million)
Table 11.78 Allogeneic Cell Therapy Market for Diabetic Foot Ulcer: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.79 Allogeneic Cell Therapy Market for Others: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.80 Allogeneic Cell Therapy Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Million)
Table 11.81 Allogeneic Cell Therapy Market for Post Transplant Infections: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.82 Allogeneic Cell Therapy Market for Cardiovascular Disorders: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.83 Allogeneic Cell Therapy Market for Autoimmune / Inflammatory Disorders: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.84 Allogeneic Cell Therapy Market for Cerebrovascular Disorders: Conservative, Base and Optimistic Scenarios, 2024-2035 (USD Million)
Table 11.85 Allogeneic Cell Therapy Market for Oncological Disorders: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.86 Allogeneic Cell Therapy Market for Musculoskeletal Disorders: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.87 Allogeneic Cell Therapy Market for Neurological Disorders: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.88 Allogeneic Cell Therapy Market for Genetic Disorders: Conservative, Base and Optimistic Scenarios, 2026-2035 (USD Million)
Table 11.89 Allogeneic Cell Therapy Market for Others: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.90 Allogeneic Cell Therapy Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Table 11.91 Allogeneic Cell Therapy Market in North America: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.92 Allogeneic Cell Therapy Market in the US: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.93 Allogeneic Cell Therapy Market in Canada: Conservative, Base and Optimistic Scenarios, 2024-2035 (USD Million)
Table 11.94 Allogeneic Cell Therapy Market in Europe: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.95 Allogeneic Cell Therapy Market in the UK: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.96 Allogeneic Cell Therapy Market in Germany: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.97 Allogeneic Cell Therapy Market in France: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.98 Allogeneic Cell Therapy Market in Italy: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.99 Allogeneic Cell Therapy Market in Spain: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.100 Allogeneic Cell Therapy Market in Rest of Europe: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.101 Allogeneic Cell Therapy Market in Asia-Pacific and Rest of the World: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.102 Allogeneic Cell Therapy Market in India: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.103 Allogeneic Cell Therapy Market in Australia: Conservative, Base and Optimistic Scenarios, 2026-2035 (USD Million)
Table 11.104 Allogeneic Cell Therapy Market in Taiwan: Conservative, Base and Optimistic Scenarios, 2027-2035 (USD Million)
Table 11.105 Allogeneic Cell Therapy Market in Japan: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.106 Allogeneic Cell Therapy Market in Korea: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.107 Allogeneic Cell Therapy Market in Malaysia: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.108 Allogeneic Cell Therapy Market in Israel: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.109 Revascor / MPC-150-IM / Rexlemestrocel-L (Mesoblast): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.110 Alofisel / Darvadstrocel / Cx601 (Takeda): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.111 MultiStem® (Athersys): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.112 Tab-cel® / tabelecleucel / ATA129 (Atara Biotherapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.113 MDR-101 (Medeor Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.114 PLX-PAD (Pluristem Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.115 OMISIRGE / Omidubicel-onlv (Gamida Cell): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.116 Orca-T (Orca Bio): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.117 Ryoncil (Mesoblast): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.118 Stempeucel® (Stempeutics Research): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.119 Viralym-M / ALVR105 / Posoleucel (Allovir): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.120 Trinity Evolution® (Orthofix): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.121 CAP-1002 (Capricor Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.122 Osteocel® Plus (NuVasive): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.123 MPC-06-ID / Rexlemestrocel-L (Mesoblast): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.124 AB-205 / E-CEL cells (Angiocrine Bioscience): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.125 allo-APZ2-OTS (RHEACELL): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.126 Trinity ELITE (Orthofix): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.127 CYP-004 (Cynata Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.128 Cytovir CMV T-cells (Kuur Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.129 CARTISTEM® (Medipost): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.130 Grafix® (Osiris Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.131 ELIXCYTE (UnicoCell Biomed): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.132 TEMCELL® HS (JCR Pharmaceutical, Mesoblast): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Table 11.133 ALLO-ASC-DFU (Anterogen): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Million)
Please reach out to our team for the details.
Source 1: https://www.sciencedirect.com/topics/engineering/allogeneic
Source 2: https://www.mskcc.org/cancer-care/clinical-trials/19-392